EBD Group is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Opening Plenary: The role of cross border collaboration in the development of a global biotech industry
Classical venture capital vs alternative financing: How to work together
Edmond de Rothschild Investment Partners
RAI Amsterdam - Street Level, Entrance C
Please note: The registration desk will be open all day.
Exhibit - Hall 12
Please note: The exhibition floor will be open all day.
Exhibit - Hall 12
After many setbacks over the last decades, promising gene and cell therapies are finally making it to the market in the US and in Europe.
The bio-medical profession, the regulators, the patients and their families rejoice over this success, but the journey is far from over. One of the key drivers and dilemmas for the bio industry is to define the right price for these groundbreaking innovations, many being curative and covering orphan diseases: A price too low potentially removes the commercial financial incentives to invest; a price too high creates budget and access problems, potentially putting at risk the sustainability of the healthcare model.
“Innovative “ pricing/payment mechanisms based on outcomes are being suggested. Is it the right and only solution? What is the way forward? The panel composed of relevant stakeholders will come together to put forward their perspective and suggest ways to create a harmonious long term sustainable market for the “buyers” (payer), the patient and the “sellers,” the bio industry.
Western companies, along with the rest of the world have been watching the extraordinary trajectory of both public and private spending on research and development (R&D) into pharmaceuticals in China. While it may be some time before we see the full impact from the surge in patenting, a multitude of Chinese home-grown biopharmaceutical companies are already capturing the attention of global markets. Coupled with recent regulatory changes to position China as global leader in pharmaceutical development, this also positions Chinese companies as an ideal R&D and commercialization partner for drug assets. This panel will discuss the impact of recent changes in China, partnering with companies in a future pharmaceutical R&D super power, and as a financial hub for economic growth.
10:00 –18:30 Please note: One-to-one meetings will take place all day depending on your partnering schedule.
Room: E 102
Welcome in Amsterdam - by Health~Holland Duration 10min.
Room E 102
With growing capital markets and innovative products in development around the world, how are biopharmacos able to leverage advances in technology, maximize opportunities for cutting costs in research, expand on a global scale, and work with both private and public partners to create access for patients? What strategies are being deployed to meet unmet medical need, take advantage of government regulations that help promote greater market access, and foster cross-border partnerships and investments? How are companies collaborating with researchers, patient advocacy groups, policy makers, payers, and stakeholders across borders to advance R&D and access to new potentially transformative therapies? Leading industry executives share their insights on what it means to be part of a global ecosystem.
Seated Luncheon – Hall 10
Grab & Go Lunch – Exhibit, Hall 12
Presented by: Therapeutic Insight by Defined Health
Why do you think the same five people make it to the final table at the World Series of Poker every single year? What are they, the luckiest guys in Las Vegas? No, it's a skill game.” – quote from the 1998 American film Rounders. According to BIO’s 2017 Industry Analysis, neurology remains the second most active disease area (behind oncology) in terms of both VC funding and licensing deals. Within the broader CNS category, neurodegerative disorders such as Alzheimer’s and Parkinson’s stand out for their associated large and growing economic and emotional burdens posed to society. Vast sums spent on R&D for such disorders over the past several decades have resulted in little tangible progress for patients, however, in retrospect, appear to have been based on relatively limited scientific evidence, such as that provided by the amyloid hypothesis in AD. While failing to deliver new therapeutic options for patients, a byproduct of such investments has been an increased level of understanding of the importance of novel biomarkers, early intervention, and novel therapeutic strategies, such as immunotherapy and gene therapy. With this as a backdrop, a number of multinational pharmas are shuttering their CNS therapeutics programs while others continue to double down on extant programs and/or diversify their portfolios. While one cannot rule out the potential for serendipitous success, those who choose to remain at the table must place a diversified series of bets that are either supported by robust science or at the very least are positioned to be at its forefront when it comes to fruition. Join us as we discuss the current state of the science, future trends, and potential strategies to mitigate risk and capture the opportunity presented by dealmaking in the neurodegeneration space.
Room: E 102
Presenter: Olaf Koenig – Business Development Director
13:45 Bristol-Myers Squibb
Presenter: Paul Biondi – Senior VP, Head Business Development
Presenter: Richa Wilson – Associate Director
Presenter: Avaleigh Milne – Senior Manager, Immunology and Infectious Disease, Genentech Partnering
Presenter: Matthieu Lebrun – Head, Out-Licensing, Global Business Development & Licensing
14:45 Eli Lilly and Company
Presenter: Johnston Erwin – VP, Corporate Business Development
Presenter: Phil L’Huillier – Head, European Innovation Hub
Presenter: Didier Landais – Global Head of Licensing
Presenter: Margarita Chavez – Managing Director
15:45 Johnson & Johnson Innovation
16:00 Boehringer Ingelheim
Presenter: Bernd Nosse – Global Head BD&L Technologies
16:15 Novartis Pharma
Presenter: Dimitris Lizos – Global BD&L, Head Search and Evaluation, Ophthalmology and Respiratory
Antimicrobial resistance (AMR) has been identified as an urgent public health priority by global policymakers, and the issue has been prominently featured by the US government, United Nations, G7 and G20. According to conservative estimates, AMR causes 700,000 deaths annually across the world. By 2050, it is projected that resistant infections will cause 10 million deaths annually. To alter this dire trajectory, new antibiotics are critically needed. However, the current market failure for antibiotics is a significant barrier to innovation, and as a result, the pipeline is thin and R&D investment has waned in recent years. This session will review progress on various innovative commercial solutions and programs designed to foster innovation in antimicrobial product development.
An increasing number of financing alternatives to traditional VC funding are available for life sciences companies. The panel will provide a perspective on alternative financing options, ranging from technology transfer and angel investing to venture debt and capital markets. Our speakers will explore the attributes of the different alternatives, as well as how they can work together with VC funding to ensure successful partnerships.
The recent outbreaks of Ebola, MERS and Zika have served as a wake-up call about our lack of global preparedness for potential pandemic infectious disease threats. Policy leaders, vaccine stakeholders and industry have all been working to resolve the challenges of developing vaccines where commercial incentives are limited. At the Davos World Economic Forum in January 2017, the global community launched an ambitious new initiative to stimulate the development of vaccines to help respond to public health crises: the Coalition for Epidemic Preparedness Innovations or CEPI. Co-founded by the Bill and Melinda Gates Foundation, the World Economic Forum, Wellcome Trust and the governments of Norway and India, CEPI aims to finance and coordinate the early-stage development of new vaccines against priority threats. Panelists will discuss the current status of industry proposals as well as next steps and follow-on RFPs. They will also discuss the role of CEPI in driving global preparedness activities, specifically whether CEPI is the right solution to fill these preparedness gaps, and, if so, how the structure of CEPI should be built to encourage industry participation while helping ensure a faster global response.
Room: E 103
Room: E 103
Presented by: Therapeutic Insight by Defined Health
As immuno-oncology (IO) continues to be at the forefront of efforts to improve outcomes in cancer, even offering the possibility of curing some patients, biopharma appears more than ever before to be adopting a strategy of spreading its bets. However, rationally deciding on what to advance or acquire, and accessing these at ever-increasing price tags, has ramped up the complexity of building cancer portfolios.
Companies are challenged with such a large number of promising options, complicating balancing scientific risk of early/novel IO targets with the commercial risk of the nth checkpoint inhibitor or a later entry CAR T-cell therapy, for example. This panel will attempt to provide some vision into the future of this complex and dynamic space and will highlight key themes that may show us where the next wave of innovation may come, where there may be white space in the biology, and, importantly for investment in clinical development, what biopharma will be looking for from IO-centric newcos.
LOCATION: The Royal Concertgebouw | Concertgebouwplein 10 | 1071 LN Amsterdam
It was Bernard Haitink who once praised The Concertgebouw as the best instrument of the orchestra that it houses. That must have been what prominent Amsterdam residents had in mind when they decided in 1881 to gift the capital city with a majestic concert hall. Seven years later, the swampy fields just outside the city limits boasted a wonder of neoclassical architecture, The Concertgebouw. Nowadays, just like the celebrated Royal Concertgebouw Orchestra, this fantastic concert hall enjoys worldwide renown.
18:45–19:15 Shuttle buses depart from the conference center to the evening event.
21:00–22:00 Shuttle buses depart from the evening event to all conference hotels.